George Wilding, MD Print Friendly PageFaculty, University of Wisconsin School of Medicine and Public Health
George Wilding, MD, was named Interim Director in 2002 and was Director of the University of Wisconsin Carbone Cancer Center from 2004 to 2013. A nationally renowned prostate cancer researcher, Wilding is the Donald and Marilyn Anderson professor of medicine.
A native of Everett, Massachusetts, Wilding graduated from the University of Massachusetts Medical School, where he also completed his internship and residency in Internal Medicine. He underwent training in Medical Oncology within the Medicine Branch at the National Cancer Institute. He has a master's degree (pharmacology) from Pennsylvania State University and bachelor's degrees from Tufts University (chemical engineering and biology).
UW Health Clinics
|Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.|
UW School of Medicine and Public Health
|Department of Medicine|
Professional Certifications and Education
National Cancer Institute, NIH, Bethesda, MD
University of Massachusetts Medical School, Worcester
University of Massachusetts Medical School, Worcester
University of Massachusetts Medical School, Worcester, MA, 1980
In his clinical practice, Wilding sees patients with genitourinary cancers, including prostate, kidney, testicular and bladder cancers. From 1995 to 2003, he directed the UW Carbone Cancer Center Experimental Therapeutics Program, which seeks to identify new anti-cancer agents in the laboratory and translate them into clinical treatments with human patients. He served as chairman of the Genitourinary Cancer Committee of the Eastern Cooperative Oncology Group, a National Cancer Institute (NCI)-sponsored clinical research group for 10 years until 2003, and serves on numerous NCI, industry and foundation advisory and review boards.
Mehraein-Ghomi F Kegel SJ Church DR Schmidt JS Reuter QR Saphner EL Basu HS Wilding G .
Targeting androgen receptor and JunD interaction for prevention of prostate cancer progression. Prostate. 2014 May;74(7):792-803
[PubMed ID: 24647988]
Deming DA Ninan J Bailey HH Kolesar JM Eickhoff J Reid JM Ames MM McGovern RM Alberti D Marnocha R Espinoza-Delgado I Wright J Wilding G Schelman WR .
A Phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumors. Invest New Drugs. 2014 Apr;32(2):323-9
[PubMed ID: 24114123]
Schelman WR Mohammed TA Traynor AM Kolesar JM Marnocha RM Eickhoff J Keppen M Alberti DB Wilding G Takebe N Liu G .
A phase I study of AT-101 with cisplatin and etoposide in patients with advanced solid tumors with an expanded cohort in extensive-stage small cell lung cancer. Invest New Drugs. 2014 Apr;32(2):295-302
[PubMed ID: 23860642]
Lang JM Wallace M Becker JT Eickhoff JC Buehring B Binkley N Staab MJ Wilding G Liu G Malkovsky M McNeel DG .
A randomized phase II trial evaluating different schedules of zoledronic acid on bone mineral density in patients with prostate cancer beginning androgen deprivation therapy. Clin Genitourin Cancer. 2013 Dec;11(4):407-15
[PubMed ID: 23835291]
Schelman WR Traynor AM Holen KD Kolesar JM Attia S Hoang T Eickhoff J Jiang Z Alberti D Marnocha R Reid JM Ames MM McGovern RM Espinoza-Delgado I Wright JJ Wilding G Bailey HH .
A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies. Invest New Drugs. 2013 Dec;31(6):1539-46
[PubMed ID: 24114121]
Kolesar JM Traynor AM Holen KD Hoang T Seo S Kim K Alberti D Espinoza-Delgado I Wright JJ Wilding G Bailey HH Schelman WR .
Vorinostat in combination with bortezomib in patients with advanced malignancies directly alters transcription of target genes. Cancer Chemother Pharmacol. 2013 Sep;72(3):661-7
[PubMed ID: 23903894]
Gee J Bailey H Kim K Kolesar J Havighurst T Tutsch KD See W Cohen MB Street N Levan L Jarrard D Wilding G .
Phase II open label, multi-center clinical trial of modulation of intermediate endpoint biomarkers by 1α-hydroxyvitamin D2 in patients with clinically localized prostate cancer and high grade pin. Prostate. 2013 Jun;73(9):970-8
[PubMed ID: 23335089]
Cetnar J Wilding G McNeel D LoConte NK McFarland TA Eickhoff J Liu G .
A phase 1/1b study of satraplatin (JM-216) in combination with docetaxel in patients with advanced solid tumors and metastatic castrate-resistant prostate cancer. Urol Oncol. 2013 May;31(4):436-41
[PubMed ID: 21481618]
Liu G Chen YH Kolesar J Huang W Dipaola R Pins M Carducci M Stein M Bubley GJ Wilding G .
Eastern Cooperative Oncology Group Phase II Trial of lapatinib in men with biochemically relapsed, androgen dependent prostate cancer. Urol Oncol. 2013 Feb;31(2):211-8
[PubMed ID: 21784672]
McNeel DG Smith HA Eickhoff JC Lang JM Staab MJ Wilding G Liu G .
Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer. Cancer Immunol Immunother. 2012 Jul;61(7):1137-47
[PubMed ID: 22210552]
Liu G Chen YH Dipaola R Carducci M Wilding G .
Phase II trial of weekly ixabepilone in men with metastatic castrate-resistant prostate cancer (E3803): a trial of the Eastern Cooperative Oncology Group. Clin Genitourin Cancer. 2012 Jun;10(2):99-105
[PubMed ID: 22386239]
Holen K DiPaola R Liu G Tan AR Wilding G Hsu K Agrawal N Chen C Xue L Rosenberg E Stein M .
A phase I trial of MK-0731, a kinesin spindle protein (KSP) inhibitor, in patients with solid tumors. Invest New Drugs. 2012 Jun;30(3):1088-95
[PubMed ID: 21424701]
Tevaarwerk A Wilding G Eickhoff J Chappell R Sidor C Arnott J Bailey H Schelman W Liu G .
Phase I study of continuous MKC-1 in patients with advanced or metastatic solid malignancies using the modified Time-to-Event Continual Reassessment Method (TITE-CRM) dose escalation design. Invest New Drugs. 2012 Jun;30(3):1039-45
[PubMed ID: 21225315]
Bruce JY Eickhoff J Pili R Logan T Carducci M Arnott J Treston A Wilding G Liu G .
A phase II study of 2-methoxyestradiol nanocrystal colloidal dispersion alone and in combination with sunitinib malate in patients with metastatic renal cell carcinoma progressing on sunitinib malate. Invest New Drugs. 2012 Apr;30(2):794-802
[PubMed ID: 21174224]
Liu G Jeraj R Vanderhoek M Perlman S Kolesar J Harrison M Simoncic U Eickhoff J Carmichael L Chao B Marnocha R Ivy P Wilding G .
Pharmacodynamic study using FLT PET/CT in patients with renal cell cancer and other solid malignancies treated with sunitinib malate. Clin Cancer Res. 2011 Dec 15;17(24):7634-44
[PubMed ID: 22038997]
Harrison MR Hahn NM Pili R Oh WK Hammers H Sweeney C Kim K Perlman S Arnott J Sidor C Wilding G Liu G .
A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC). Invest New Drugs. 2011 Dec;29(6):1465-74
[PubMed ID: 20499131]
Lang JM Kaikobad MR Wallace M Staab MJ Horvath DL Wilding G Liu G Eickhoff JC McNeel DG Malkovsky M .
Pilot trial of interleukin-2 and zoledronic acid to augment γδ T cells as treatment for patients with refractory renal cell carcinoma. Cancer Immunol Immunother. 2011 Oct;60(10):1447-60
[PubMed ID: 21647691]
Traynor AM Thomas JP Ramanathan RK Mody TD Alberti D Wilding G Bailey HH .
Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignancies. Invest New Drugs. 2011 Apr;29(2):316-22
[PubMed ID: 19997959]
Basu HS Mahlum A Mehraein-Ghomi F Kegel SJ Guo S Peters NR Wilding G .
Pretreatment with anti-oxidants sensitizes oxidatively stressed human cancer cells to growth inhibitory effect of suberoylanilide hydroxamic acid (SAHA). Cancer Chemother Pharmacol. 2011 Mar;67(3):705-15
[PubMed ID: 20512578]
Holen KD Belani CP Wilding G Ramalingam S Volkman JL Ramanathan RK Vasist LS Bowen CJ Hodge JP Dar MM Ho PT .
A first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II dose. Cancer Chemother Pharmacol. 2011 Feb;67(2):447-54
[PubMed ID: 20461380]